| http://www.w3.org/ns/prov#value | - In an era of socialized medicine and cost containment in many parts of the world, it begs the question: Would payers especially governments be willing to pay double for a therapy that might deliver an extra 6% response (depending on Phase 3 trial results) especially with the additional side effects that would be expected to come with a regimen that is twice the duration??.
|
